Ir para o conteúdo principal

Evaxion Biotech AS (NASDAQ: EVAX) — Perfil da empresa, notícias e dados financeiros

Logo de Evaxion Biotech AS
EVAX Evaxion Biotech AS
Evaxion Biotech AS primary media
Perfil da empresa

Evaxion Biotech AS

Evaxion Biotech AS (NASDAQ:EVAX) is a pioneering entity concentrated on leveraging artificial intelligence (AI) to discover and develop novel immunotherapies for cancer, infectious diseases, and autoimmune disorders. Operating at the intersection of biotechnology and AI, Evaxion aims to revolutionize the way diseases are treated by harnessing the power of the human immune system, guided by cutting-edge computational platforms. The company's projects span a wide range of applications, from personalized cancer vaccines to broad-spectrum antibacterials, with the objective to significantly improve patient outcomes by making therapies more effective, safer, and accessible. Committed to innovation, Evaxion is driven by a fervent desire to address unmet medical needs, positioning itself as a forward-thinking player in the biotech industry.

Resumo

Public USParticipação acionária
2008Ano de fundação
49Funcionários
Copenhagen, DenmarkSede
Carregando mapa...
Presença global

Operações

Todos os locais
Kingdom of Denmark

Produtos e/ou serviços de Evaxion Biotech AS

  • PIONEER personalized cancer immunotherapy, utilizing AI to design patient-specific treatments.
  • EVX-01, a personalized cancer vaccine targeting melanoma, leveraging AI for enhanced specificity.
  • EVX-02, another personalized cancer vaccine, aiming at adjuvant melanoma but with distinct antigens.
  • EVX-03, focusing on DNA-based therapies for infectious diseases, harnessing AI for rapid pathogen identification.
  • AI-powered platform for rapid antibody discovery, streamlining therapeutic antibody development against infectious diseases.
  • EVX-B1, a vaccine in development against Staphylococcus aureus, intending to prevent infections in healthcare settings.

equipe executiva do Evaxion Biotech AS

  • Helen Katrina Tayton-MartinChief Executive Officer
  • Andreas Holm MattssonFounder & Chief AI Officer
  • Thomas Frederik SchmidtChief Financial Officer
  • Birgitte RonoChief Scientific Officer & COO
  • Benjamin Ole WolthersVice President of Clinical Development

Principais indicadores financeiros

Resultados divulgados pela Evaxion Biotech AS, em USD.

Cap. de mercado
28,1 mi
Receita (TTM)
7,5 mi
P/L
—
LPA (diluído, TTM)
-1.0
Dividend yield
—
Margem de lucro
-115.5%
Receita e lucro anuais da Evaxion Biotech AS
Fim do ano fiscalReceitaResultado operacionalLucro líquido
7,5 mi-9,2 mi-7,7 mi
3,3 mi-14,7 mi-10,6 mi
73 mil-22,2 mi-22,1 mi
0-25,3 mi-23,2 mi